Backstrom Jay T. 4

What Happened

• Jay T. Backstrom, a director of Agios Pharmaceuticals (AGIO), was granted two equity awards on June 18, 2026: 2,927 restricted stock units (RSUs) and 14,950 option-type awards (total 17,877 derivative units). Both were awarded at a $0.00 grant price (no cash exchanged at grant).

Key Details

• Transaction date: June 18, 2026; reported on Form 4 filed June 23, 2026.
• Grant price: $0.00 for both awards (award/grant code A).
• Vesting: Both awards vest 100% on June 18, 2027.
• Delivery: For the RSUs, vested shares will be delivered to the reporting person within three business days after vesting.
• Shares owned after transaction: Not disclosed in the excerpted filing.
• Filing timeliness: Form 4 was filed June 23, 2026 — after the June 18 transaction; this appears to be one business day past the normal two-business-day reporting deadline for Form 4.

Context

• The 2,927 RSUs represent contingent rights to receive one share each upon vesting; the 14,950 awards are option-type grants whose underlying shares vest on the same date. No shares were sold or purchased on market — these are forward-looking compensation awards that will convert to stock only if/when they vest. Such grants are common in director compensation and do not by themselves indicate immediate buying or selling of stock.